GBA's "2021 Stock Phantasma"

These findings build upon Lexaria's recent announcement that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using anin vitroscreening assay in infected cells in its study VIRAL-C21-3.

"These are the best results Lexaria has ever generated demonstrating our technology's ability to more effectively deliver antiviral drugs when taken orally," said Chris Bunka, CEO of Lexaria. "We are starting to see circulating drug levels in the bloodstream that are twice or even three-times higher with DehydraTECH than without, which could greatly enhance opportunities to treat viral infections via oral drug delivery."
 
The study evaluated peak concentration ("Maximum Concentration" or "Cmax"**) and total drug delivery into the rodent bloodstream ("Area Under the Curve" or "AUClast***"), whereby the rats were evaluated over a period of 48 hours after dosing to derive the measured AUClast over the entire period. Blood quantitation for remdesivir was performed by measuring it in its GS-441524* nucleoside analogue metabolite form because remdesivir is a prodrug that is known to be rapidly converted by host cells into its active form following administration.

The findings were statistically significant only in the case of ebastine AUClast gains upon administration of DehydraTECH formulations versus the concentration matched controls, suggesting that larger sample sizes may have been necessary to overcome the observed variability.
 
Lexaria Bioscience Corp. (LEXX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD

6.67+0.12 (+1.83%)
At close: June 14 4:00PM EDT
$7.20+0.53 (7.95%)
Pre-Market:09:24AM EDT
 

Lelie's Retakes Breakout- or did it! Dropped that secondary...
June 7, 2021


Leslie's broke out above a 30.95 buy point on Thursday but couldn't hold it. Today, it's giving it another shot.
 
this is the one australian bioplastic that i've kept--it's not flashy but they have factories and profits. they missed in earnings last month and got hammered, but made most of it up last night with news of an increase in biodegradable bag placement at woolworths, which i guess is australia's biggest supermarket.

Secos Group Ltd
ASX: SES
0.28 AUD+0.055 (24.44%)today
Jun 15, 4:10 PM GMT+10 ·
 
Ok things moved a little quick for me --

I have an $8.40 limit in for TTSH>>>

Got a small partial fill at $8.15-- they are making me go limit which I hate you have to guess...
 
stonedinvestor said:
Ok things moved a little quick for me --

I have an $8.40 limit in for TTSH>>>

Got a small partial fill at $8.15-- they are making me go limit which I hate you have to guess...
More...
they should have updated data on the pricing soon, just not first thing
 
A)Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler 12:22 JNCE, GILD Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $20 price target on Jounce Therapeutics (JNCE), which will receive a $25M milestone from partner Gilead (GILD) for IND clearance for anti-CCR8 antibody GS-1811. Jounce, which expects to initiate eight expansion cohorts in 2H21, now holds pro forma cash of roughly $296M to advance its innovative I-O pipeline, Tenthoff tells investors in a research note.

B)Clearside reported 'impressive' data in wet AMD, says Roth Capital 11:48 CLSD

(JNCE)$8.19<----// $8.45 HOD High volume

Clearside Biomedical, Inc. (CLSD) Imense vol

4.0661+1.0461 (+34.6391%)<----// HOD $4.79
As of 2:51PM EDT. Market open.

Clearside success with Xipere can derisk pipeline, says Roth Capital 06/02 CLSD, BHC After Clearside Biomedical (CLSD) and partner Bausch Health Companies (BHC) announced that the FDA has accepted the resubmitted New Drug Application for Xipere, Roth Capital analyst Zegbeh Jallah noted that progress had been slowed by manufacturing issues that resulted in a CRL. However, based on the NDA acceptance, the FDA's concerns have now been addressed, said Jallah, who is "clearly very bullish" on approval in October and a commercial launch in 2022. The analyst, who thinks approval of Xipere should derisk Clearside's SCS Microinjector and give Clearside some non-dilutive capital to advance its pipeline, keeps a Buy rating on the shares and identifies the stock as a 2021 top pick.
 
You must log in or register to reply here.
Back
Top